Brian Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Brian Tan has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Angela Christine Roberts
Department of Computer Science, Western University, London, Ontario, Canada
6 shared publications - Angela K. Troyer
Neuropsychology & Cognitive Health, Baycrest Hospital
5 shared publications - Anthony E. Lang
Division of Neurology, Department of Medicine University of Toronto Toronto ON Canada
5 shared publications Donna Kwan
Centre for Neuroscience Studies, Queen's University, Kingston, Canada
5 shared publications- Joel Ramirez
Dr. Sandra E. Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
5 shared publications - Paula M. McLaughlin
Ontario Neurodegenerative Disease Research Initiative, Toronto, ON Canada
5 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-18
Maximizing fidelity of neuropsychology assessments in fully remote studies
Remote, interdisciplinary, observational clinical studies and clinical trials are becoming increasingly common, yet they pose challenges for maintaining data fidelity-the accuracy, completeness, and consistency of data. This study aimed to (1) evaluate the data fidelity of a remote videoconference-administered neuropsychology protocol within the context of an observational clinical trial; (2) develop three methodological roadmaps to support data fidelity for remote neuropsychological research; and (3) characterize the sample and their performance. One hundred forty eight participants (62% female; median age = 67, mean education = 15.1 years) completed the protocol. Data were analyzed using descriptive statistics. On average, 5.59 queries (i.e., data quality flags) per participant were generated during the data monitoring phase, decreasing to 0.30 during the cleaning and curation pipeline phase. Overall, missing data were minimal (0.34%). Virtual environment factors (e.g., internet connectivity and distractions) had minimal impact on data quality; only 8 participants (5.4%) had 1-2 tasks affected resulting in missing data. The fidelity of the remote videoconference-administered protocol was comparable to that of in-person assessments. These findings suggest that remote videoconference-administered neuropsychological assessment can yield high-fidelity data when supported by rigorous quality assurance and quality control procedures. The proposed roadmaps provide practical guidance for future remote neuropsychological research and support the broader adoption of standardized telehealth methodologies in the study of neurodegenerative diseases.
- 15 April 2026
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- p. 1-18
Open AccessMaximizing fidelity of neuropsychology assessments in fully remote studies
Remote, interdisciplinary, observational clinical studies and clinical trials are becoming increasingly common, yet they pose challenges for maintaining data fidelity-the accuracy, completeness, and consistency of data. This study aimed to (1) evaluate the data fidelity of a remote videoconference-administered neuropsychology protocol within the context of an observational clinical trial; (2) develop three methodological roadmaps to support data fidelity for remote neuropsychological research; and (3) characterize the sample and their performance. One hundred forty eight participants (62% female; median age = 67, mean education = 15.1 years) completed the protocol. Data were analyzed using descriptive statistics. On average, 5.59 queries (i.e., data quality flags) per participant were generated during the data monitoring phase, decreasing to 0.30 during the cleaning and curation pipeline phase. Overall, missing data were minimal (0.34%). Virtual environment factors (e.g., internet connectivity and distractions) had minimal impact on data quality; only 8 participants (5.4%) had 1-2 tasks affected resulting in missing data. The fidelity of the remote videoconference-administered protocol was comparable to that of in-person assessments. These findings suggest that remote videoconference-administered neuropsychological assessment can yield high-fidelity data when supported by rigorous quality assurance and quality control procedures. The proposed roadmaps provide practical guidance for future remote neuropsychological research and support the broader adoption of standardized telehealth methodologies in the study of neurodegenerative diseases.
- 7 June 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 1115-1126
Subcortical white matter hyperintensities and motor function in parkinson’s disease: findings from the ONDRI study
Background Motor signs, such as rigidity, bradykinesia, tremor, gait and balance impairment, are hallmark features of idiopathic Parkinson’s disease (PD). The basal ganglia, involved in voluntary and automatic movements, are affected by reduced dopaminergic activity, contributing to motor signs in PD. Motor signs may be exacerbated by cortical white matter hyperintensities (WMH), but the relationship between basal ganglia WMH and motor signs remains unclear. Objective To investigate the association between subcortical WMH burden and motor severity in PD participants. Method This cross-sectional study included 140 PD participants from the Ontario Neurodegenerative Disease Research Initiative (ONDRI). The relative WMH (i.e, percentage) in the whole brain, frontal, temporal, parietal, occipital lobes, and basal ganglia+thalamus (BGT) were calculated. Adjusted regression models were used to test the associations between WMH and motor signs. WMH burden was stratified by quartiles, and Analysis of Covariance was applied to determine which WMH quartile most affected motor signs. Results Increased WMH burden in BGT was associated with better motor function. In contrast, WMH burden in cortical brain regions, i.e., frontal, parietal, temporal, and occipital lobes, was not associated with worse motor signs. Participants with larger BGT WMH volumes exhibited better motor function compared to those in lower quartiles Conclusion Hyperintense lesions in the basal ganglia+thalamus were significantly associated with better motor function, suggesting that disruption of inhibitory basal ganglia circuitry may recalibrate motor output. These findings raise novel hypotheses about circuit-level modulation in Parkinson’s disease and may guide future mechanistic and therapeutic investigations. However, as the results are correlational, they do not imply causality.
- 7 June 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 1115-1126
Subcortical white matter hyperintensities and motor function in parkinson’s disease: findings from the ONDRI study
Background Motor signs, such as rigidity, bradykinesia, tremor, gait and balance impairment, are hallmark features of idiopathic Parkinson’s disease (PD). The basal ganglia, involved in voluntary and automatic movements, are affected by reduced dopaminergic activity, contributing to motor signs in PD. Motor signs may be exacerbated by cortical white matter hyperintensities (WMH), but the relationship between basal ganglia WMH and motor signs remains unclear. Objective To investigate the association between subcortical WMH burden and motor severity in PD participants. Method This cross-sectional study included 140 PD participants from the Ontario Neurodegenerative Disease Research Initiative (ONDRI). The relative WMH (i.e, percentage) in the whole brain, frontal, temporal, parietal, occipital lobes, and basal ganglia+thalamus (BGT) were calculated. Adjusted regression models were used to test the associations between WMH and motor signs. WMH burden was stratified by quartiles, and Analysis of Covariance was applied to determine which WMH quartile most affected motor signs. Results Increased WMH burden in BGT was associated with better motor function. In contrast, WMH burden in cortical brain regions, i.e., frontal, parietal, temporal, and occipital lobes, was not associated with worse motor signs. Participants with larger BGT WMH volumes exhibited better motor function compared to those in lower quartiles Conclusion Hyperintense lesions in the basal ganglia+thalamus were significantly associated with better motor function, suggesting that disruption of inhibitory basal ganglia circuitry may recalibrate motor output. These findings raise novel hypotheses about circuit-level modulation in Parkinson’s disease and may guide future mechanistic and therapeutic investigations. However, as the results are correlational, they do not imply causality.
- Open Access
- 22 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Maximizing Fidelity of Neuropsychology Assessments in Fully Remote Studies (Preprint)
BACKGROUND Remote, interdisciplinary, observational clinical studies and clinical trials are increasingly emerging in the scientific literature. Remote videoconference-based neuropsychological assessment offers numerous advantages, including improved access to care, reduced travel burden, and the ability to monitor patients over time. However, such methodologies present challenges, particularly regarding the fidelity of collected data. Data fidelity, defined as the accuracy, completeness, and consistency of data, can be compromised by technical issues, variability in testing environments, and risks of data loss. These challenges necessitate the development of robust, standardized protocols to ensure high-quality data collection and analysis. OBJECTIVE This study aimed (1) to evaluate the data fidelity of a remote videoconference-administered neuropsychology protocol in the context of the Health in Aging, Neurodegenerative Diseases, and Dementias in Ontario (HANDDS-ONT) study, guided by the Ontario Neurodegenerative Disease Research Initiative (ONDRI); (2) to generate three roadmaps to support data fidelity procedures for future remote neuropsychological research; and (3) to characterize the sample and their neuropsychological assessment performance. Quality assurance and quality control procedures were implemented, and missing data, virtual environment-related errors, and outcomes of quality assurance and quality control measures were evaluated to assess data fidelity. METHODS 148 participants (62% female; median age=67, mean=15.1 education years) completed the neuropsychology protocol. Data were analyzed as descriptive statistics. RESULTS Implementing our quality assurance and control procedures, the average number of queries per participant was 5.59 during the data monitoring phase and 0.30 during the cleaning and curation pipeline phase, with only 0.34% of data missing. Virtual environment factors, such as internet connectivity and distractions, had minimal impact on data quality as only 8 participants (5.4%) had 1-2 tasks impacted by the virtual environment resulting in missing data. The fidelity of the remote videoconference-administered neuropsychology protocol was comparable to that of in-person assessments, and our procedures effectively minimized missing data and reduced the need for data corrections. The study highlighted the feasibility of collecting reliable neuropsychology data remotely while identifying practical adaptations to mitigate potential challenges. CONCLUSIONS The current study highlights the potential of remote videoconference-administered neuropsychological assessment to deliver high-fidelity data in clinical and research settings. The protocol performed similarly to an in-person neuropsychology protocol as it pertained to quality control indices (i.e., missingness and number of data corrections needed), and few virtual environment-related factors impacted data missingness. Quality assurance and quality control measures were crucial for ensuring the data were collected robustly remotely. The proposed roadmaps offer a template for future studies, addressing common challenges in remote neuropsychological testing and enabling wider adoption of telehealth methodologies. By advancing standardized protocols, this research supports the ongoing evolution of remote, interdisciplinary approaches to studying and managing neurodegenerative diseases. CLINICALTRIAL CTO Project ID #3589
- 22 April 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMaximizing Fidelity of Neuropsychology Assessments in Fully Remote Studies (Preprint)
BACKGROUND Remote, interdisciplinary, observational clinical studies and clinical trials are increasingly emerging in the scientific literature. Remote videoconference-based neuropsychological assessment offers numerous advantages, including improved access to care, reduced travel burden, and the ability to monitor patients over time. However, such methodologies present challenges, particularly regarding the fidelity of collected data. Data fidelity, defined as the accuracy, completeness, and consistency of data, can be compromised by technical issues, variability in testing environments, and risks of data loss. These challenges necessitate the development of robust, standardized protocols to ensure high-quality data collection and analysis. OBJECTIVE This study aimed (1) to evaluate the data fidelity of a remote videoconference-administered neuropsychology protocol in the context of the Health in Aging, Neurodegenerative Diseases, and Dementias in Ontario (HANDDS-ONT) study, guided by the Ontario Neurodegenerative Disease Research Initiative (ONDRI); (2) to generate three roadmaps to support data fidelity procedures for future remote neuropsychological research; and (3) to characterize the sample and their neuropsychological assessment performance. Quality assurance and quality control procedures were implemented, and missing data, virtual environment-related errors, and outcomes of quality assurance and quality control measures were evaluated to assess data fidelity. METHODS 148 participants (62% female; median age=67, mean=15.1 education years) completed the neuropsychology protocol. Data were analyzed as descriptive statistics. RESULTS Implementing our quality assurance and control procedures, the average number of queries per participant was 5.59 during the data monitoring phase and 0.30 during the cleaning and curation pipeline phase, with only 0.34% of data missing. Virtual environment factors, such as internet connectivity and distractions, had minimal impact on data quality as only 8 participants (5.4%) had 1-2 tasks impacted by the virtual environment resulting in missing data. The fidelity of the remote videoconference-administered neuropsychology protocol was comparable to that of in-person assessments, and our procedures effectively minimized missing data and reduced the need for data corrections. The study highlighted the feasibility of collecting reliable neuropsychology data remotely while identifying practical adaptations to mitigate potential challenges. CONCLUSIONS The current study highlights the potential of remote videoconference-administered neuropsychological assessment to deliver high-fidelity data in clinical and research settings. The protocol performed similarly to an in-person neuropsychology protocol as it pertained to quality control indices (i.e., missingness and number of data corrections needed), and few virtual environment-related factors impacted data missingness. Quality assurance and quality control measures were crucial for ensuring the data were collected robustly remotely. The proposed roadmaps offer a template for future studies, addressing common challenges in remote neuropsychological testing and enabling wider adoption of telehealth methodologies. By advancing standardized protocols, this research supports the ongoing evolution of remote, interdisciplinary approaches to studying and managing neurodegenerative diseases. CLINICALTRIAL CTO Project ID #3589
- 8 May 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4540-4550
History of traumatic brain injury is associated with increased grey-matter loss in patients with mild cognitive impairment
Objectives To investigate whether a history of traumatic brain injury (TBI) is associated with greater long-term grey-matter loss in patients with mild cognitive impairment (MCI). Methods 85 patients with MCI were identified, including 26 with a previous history of traumatic brain injury (MCI[TBI-]) and 59 without (MCI[TBI+]). Cortical thickness was evaluated by segmenting T1-weighted MRI scans acquired longitudinally over a 2-year period. Bayesian multilevel modelling was used to evaluate group differences in baseline cortical thickness and longitudinal change, as well as group differences in neuropsychological measures of executive function. Results At baseline, the MCI[TBI+] group had less grey matter within right entorhinal, left medial orbitofrontal and inferior temporal cortex areas bilaterally. Longitudinally, the MCI[TBI+] group also exhibited greater longitudinal declines in left rostral middle frontal, the left caudal middle frontal and left lateral orbitofrontal areas sover the span of 2 years (median = 1–2%, 90%HDI [−0.01%: −0.001%], probability of direction (PD) = 90–99%). The MCI[TBI+] group also displayed greater longitudinal declines in Trail-Making-Test (TMT)-derived ratio (median: 0.737%, 90%HDI: [0.229%: 1.31%], PD = 98.8%) and differences scores (median: 20.6%, 90%HDI: [−5.17%: 43.2%], PD = 91.7%). Conclusions Our findings support the notion that patients with MCI and a history of TBI are at risk of accelerated neurodegeneration, displaying greatest evidence for cortical atrophy within the left middle frontal and lateral orbitofrontal frontal cortex. Importantly, these results suggest that long-term TBI-mediated atrophy is more pronounced in areas vulnerable to TBI-related mechanical injury, highlighting their potential relevance for diagnostic forms of intervention in TBI.
- 8 May 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4540-4550
History of traumatic brain injury is associated with increased grey-matter loss in patients with mild cognitive impairment
Objectives To investigate whether a history of traumatic brain injury (TBI) is associated with greater long-term grey-matter loss in patients with mild cognitive impairment (MCI). Methods 85 patients with MCI were identified, including 26 with a previous history of traumatic brain injury (MCI[TBI-]) and 59 without (MCI[TBI+]). Cortical thickness was evaluated by segmenting T1-weighted MRI scans acquired longitudinally over a 2-year period. Bayesian multilevel modelling was used to evaluate group differences in baseline cortical thickness and longitudinal change, as well as group differences in neuropsychological measures of executive function. Results At baseline, the MCI[TBI+] group had less grey matter within right entorhinal, left medial orbitofrontal and inferior temporal cortex areas bilaterally. Longitudinally, the MCI[TBI+] group also exhibited greater longitudinal declines in left rostral middle frontal, the left caudal middle frontal and left lateral orbitofrontal areas sover the span of 2 years (median = 1–2%, 90%HDI [−0.01%: −0.001%], probability of direction (PD) = 90–99%). The MCI[TBI+] group also displayed greater longitudinal declines in Trail-Making-Test (TMT)-derived ratio (median: 0.737%, 90%HDI: [0.229%: 1.31%], PD = 98.8%) and differences scores (median: 20.6%, 90%HDI: [−5.17%: 43.2%], PD = 91.7%). Conclusions Our findings support the notion that patients with MCI and a history of TBI are at risk of accelerated neurodegeneration, displaying greatest evidence for cortical atrophy within the left middle frontal and lateral orbitofrontal frontal cortex. Importantly, these results suggest that long-term TBI-mediated atrophy is more pronounced in areas vulnerable to TBI-related mechanical injury, highlighting their potential relevance for diagnostic forms of intervention in TBI.
- Open Access
- 12 March 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (4) , 2968-2979
Link among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study
INTRODUCTION: Apolipoprotein E E4 allele (APOE E4) and slow gait are independently associated with cognitive impairment and dementia. However, it is unknown whether their coexistence is associated with poorer cognitive performance and its underlying mechanism in neurodegenerative diseases.METHODS: Gait speed, APOE E4, cognition, and neuroimaging were assessed in 480 older adults with neurodegeneration. Participants were grouped by APOE E4 presence and slow gait. Mediation analyses were conducted to determine if brain structures could explain the link between these factors and cognitive performance.RESULTS: APOE E4 carriers with slow gait had the lowest global cognitive performance and smaller gray matter volumes compared to non‐APOE E4 carriers with normal gait. Coexistence of APOE E4 and slow gait best predicted global and domain‐specific poorer cognitive performances, mediated by smaller gray matter volume.DISCUSSION: Gait slowness in APOE E4 carriers with neurodegenerative diseases may indicate extensive gray matter changes associated with poor cognition.Highlights: APOE E4 and slow gait are risk factors for cognitive decline in neurodegenerative diseases. Slow gait and smaller gray matter volumes are associated, independently of APOE E4. Worse cognition in APOE E4 carriers with slow gait is explained by smaller GM volume. Gait slowness in APOE E4 carriers indicates poorer cognition‐related brain changes.
- 12 March 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (4) , 2968-2979
Open AccessLink among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study
INTRODUCTION: Apolipoprotein E E4 allele (APOE E4) and slow gait are independently associated with cognitive impairment and dementia. However, it is unknown whether their coexistence is associated with poorer cognitive performance and its underlying mechanism in neurodegenerative diseases.METHODS: Gait speed, APOE E4, cognition, and neuroimaging were assessed in 480 older adults with neurodegeneration. Participants were grouped by APOE E4 presence and slow gait. Mediation analyses were conducted to determine if brain structures could explain the link between these factors and cognitive performance.RESULTS: APOE E4 carriers with slow gait had the lowest global cognitive performance and smaller gray matter volumes compared to non‐APOE E4 carriers with normal gait. Coexistence of APOE E4 and slow gait best predicted global and domain‐specific poorer cognitive performances, mediated by smaller gray matter volume.DISCUSSION: Gait slowness in APOE E4 carriers with neurodegenerative diseases may indicate extensive gray matter changes associated with poor cognition.Highlights: APOE E4 and slow gait are risk factors for cognitive decline in neurodegenerative diseases. Slow gait and smaller gray matter volumes are associated, independently of APOE E4. Worse cognition in APOE E4 carriers with slow gait is explained by smaller GM volume. Gait slowness in APOE E4 carriers indicates poorer cognition‐related brain changes.
- 8 February 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 110, 105316
Classification and staging of Parkinson's disease using video-based eye tracking
- 8 February 2023
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 110, 105316
Classification and staging of Parkinson's disease using video-based eye tracking
- Open Access
- 3 January 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (1)
Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke
Background: Cerebral small vessel disease is associated with higher ratios of soluble‐epoxide hydrolase derived linoleic acid diols (12,13‐dihydroxyoctadecenoic acid [DiHOME] and 9,10‐DiHOME) to their parent epoxides (12(13)‐epoxyoctadecenoic acid [EpOME] and 9(10)‐EpOME); however, the relationship has not yet been examined in stroke. Methods and Results: Participants with mild to moderate small vessel stroke or large vessel stroke were selected based on clinical and imaging criteria. Metabolites were quantified by ultra‐high‐performance liquid chromatography–mass spectrometry. Volumes of stroke, lacunes, white matter hyperintensities, magnetic resonance imaging visible perivascular spaces, and free water diffusion were quantified from structural and diffusion magnetic resonance imaging (3 Tesla). Adjusted linear regression models were used for analysis. Compared with participants with large vessel stroke (n=30), participants with small vessel stroke (n=50) had a higher 12,13‐DiHOME/12(13)‐EpOME ratio (β=0.251, P =0.023). The 12,13‐DiHOME/12(13)‐EpOME ratio was associated with more lacunes (β=0.266, P =0.028) but not with large vessel stroke volumes. Ratios of 12,13‐DiHOME/12(13)‐EpOME and 9,10‐DiHOME/9(10)‐EpOME were associated with greater volumes of white matter hyperintensities (β=0.364, P P P =0.011; β=0.314, P =0.006). In small vessel stroke, the 12,13‐DiHOME/12(13)‐EpOME ratio was associated with higher white matter free water diffusion (β=0.439, P =0.016), which was specific to the temporal lobe in exploratory regional analyses. The 9,10‐DiHOME/9(10)‐EpOME ratio was associated with temporal lobe atrophy (β=−0.277, P =0.031). Conclusions: Linoleic acid markers of cytochrome P450/soluble‐epoxide hydrolase activity were associated with small versus large vessel stroke, with small vessel disease markers consistent with blood brain barrier and neurovascular‐glial disruption, and temporal lobe atrophy. The findings may indicate a novel modifiable risk factor for small vessel disease and related neurodegeneration.
- 3 January 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (1)
Open AccessSoluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke
Background: Cerebral small vessel disease is associated with higher ratios of soluble‐epoxide hydrolase derived linoleic acid diols (12,13‐dihydroxyoctadecenoic acid [DiHOME] and 9,10‐DiHOME) to their parent epoxides (12(13)‐epoxyoctadecenoic acid [EpOME] and 9(10)‐EpOME); however, the relationship has not yet been examined in stroke. Methods and Results: Participants with mild to moderate small vessel stroke or large vessel stroke were selected based on clinical and imaging criteria. Metabolites were quantified by ultra‐high‐performance liquid chromatography–mass spectrometry. Volumes of stroke, lacunes, white matter hyperintensities, magnetic resonance imaging visible perivascular spaces, and free water diffusion were quantified from structural and diffusion magnetic resonance imaging (3 Tesla). Adjusted linear regression models were used for analysis. Compared with participants with large vessel stroke (n=30), participants with small vessel stroke (n=50) had a higher 12,13‐DiHOME/12(13)‐EpOME ratio (β=0.251, P =0.023). The 12,13‐DiHOME/12(13)‐EpOME ratio was associated with more lacunes (β=0.266, P =0.028) but not with large vessel stroke volumes. Ratios of 12,13‐DiHOME/12(13)‐EpOME and 9,10‐DiHOME/9(10)‐EpOME were associated with greater volumes of white matter hyperintensities (β=0.364, P P P =0.011; β=0.314, P =0.006). In small vessel stroke, the 12,13‐DiHOME/12(13)‐EpOME ratio was associated with higher white matter free water diffusion (β=0.439, P =0.016), which was specific to the temporal lobe in exploratory regional analyses. The 9,10‐DiHOME/9(10)‐EpOME ratio was associated with temporal lobe atrophy (β=−0.277, P =0.031). Conclusions: Linoleic acid markers of cytochrome P450/soluble‐epoxide hydrolase activity were associated with small versus large vessel stroke, with small vessel disease markers consistent with blood brain barrier and neurovascular‐glial disruption, and temporal lobe atrophy. The findings may indicate a novel modifiable risk factor for small vessel disease and related neurodegeneration.
- Open Access
- 28 September 2021
- Published by Springer Nature in npj Genomic Medicine
- Vol. 6 (1) , 1-9
Contribution of rare variant associations to neurodegenerative disease presentation
Genetic factors contribute to neurodegenerative diseases, with high heritability estimates across diagnoses; however, a large portion of the genetic influence remains poorly understood. Many previous studies have attempted to fill the gaps by performing linkage analyses and association studies in individual disease cohorts, but have failed to consider the clinical and pathological overlap observed across neurodegenerative diseases and the potential for genetic overlap between the phenotypes. Here, we leveraged rare variant association analyses (RVAAs) to elucidate the genetic overlap among multiple neurodegenerative diagnoses, including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia (FTD), mild cognitive impairment, and Parkinson’s disease (PD), as well as cerebrovascular disease, using the data generated with a custom-designed neurodegenerative disease gene panel in the Ontario Neurodegenerative Disease Research Initiative (ONDRI). As expected, only ~3% of ONDRI participants harboured a monogenic variant likely driving their disease presentation. Yet, when genes were binned based on previous disease associations, we observed an enrichment of putative loss of function variants in PD genes across all ONDRI cohorts. Further, individual gene-based RVAA identified significant enrichment of rare, nonsynonymous variants in PARK2 in the FTD cohort, and in NOTCH3 in the PD cohort. The results indicate that there may be greater heterogeneity in the genetic factors contributing to neurodegeneration than previously appreciated. Although the mechanisms by which these genes contribute to disease presentation must be further explored, we hypothesize they may be a result of rare variants of moderate phenotypic effect contributing to overlapping pathology and clinical features observed across neurodegenerative diagnoses.
- 28 September 2021
- Published by Springer Nature in npj Genomic Medicine
- Vol. 6 (1) , 1-9
Open AccessContribution of rare variant associations to neurodegenerative disease presentation
Genetic factors contribute to neurodegenerative diseases, with high heritability estimates across diagnoses; however, a large portion of the genetic influence remains poorly understood. Many previous studies have attempted to fill the gaps by performing linkage analyses and association studies in individual disease cohorts, but have failed to consider the clinical and pathological overlap observed across neurodegenerative diseases and the potential for genetic overlap between the phenotypes. Here, we leveraged rare variant association analyses (RVAAs) to elucidate the genetic overlap among multiple neurodegenerative diagnoses, including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia (FTD), mild cognitive impairment, and Parkinson’s disease (PD), as well as cerebrovascular disease, using the data generated with a custom-designed neurodegenerative disease gene panel in the Ontario Neurodegenerative Disease Research Initiative (ONDRI). As expected, only ~3% of ONDRI participants harboured a monogenic variant likely driving their disease presentation. Yet, when genes were binned based on previous disease associations, we observed an enrichment of putative loss of function variants in PD genes across all ONDRI cohorts. Further, individual gene-based RVAA identified significant enrichment of rare, nonsynonymous variants in PARK2 in the FTD cohort, and in NOTCH3 in the PD cohort. The results indicate that there may be greater heterogeneity in the genetic factors contributing to neurodegeneration than previously appreciated. Although the mechanisms by which these genes contribute to disease presentation must be further explored, we hypothesize they may be a result of rare variants of moderate phenotypic effect contributing to overlapping pathology and clinical features observed across neurodegenerative diagnoses.
- 1 September 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 105, 378.e1-378.e9
Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses
- 1 September 2021
- Published by Elsevier in Neurobiology of Aging
- Vol. 105, 378.e1-378.e9
Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses
- Open Access
The Ontario Neurodegenerative Disease Research Initiative
Objective: In individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results. Methods: Five disease cohorts were recruited: Alzheimer’s disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics. Results: 520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location. Conclusion: ONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.
Open AccessThe Ontario Neurodegenerative Disease Research Initiative
Objective: In individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results. Methods: Five disease cohorts were recruited: Alzheimer’s disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics. Results: 520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location. Conclusion: ONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.